cADPR induced calcium influx mediates axonal degeneration caused by paclitaxel

Ahmet Höke1

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.

Insights

Chemotherapy drug paclitaxel triggers axonal degeneration by activating Sarm1, leading to the breakdown product cyclic ADP-ribose (cADPR). This cADPR then causes calcium influx into axons, driving degeneration.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Sarm1 activation is known to mediate chemotherapy-induced axonal degeneration.
  • The precise downstream molecular mechanisms following Sarm1 activation remain largely uncharacterized.

Purpose of the Study:

  • To elucidate the downstream signaling pathway by which Sarm1 activation leads to axonal degeneration.
  • To identify the specific molecules involved in paclitaxel-induced neurotoxicity.

Main Methods:

  • Utilized cell culture models and biochemical assays to investigate the role of NAD metabolites.
  • Examined the impact of cADPR on calcium homeostasis within axons.

Main Results:

  • Demonstrated that cyclic ADP-ribose (cADPR), a breakdown product of NAD+, is a key mediator of paclitaxel-induced axonal degeneration.
  • Showcased that cADPR promotes calcium influx into axons, a critical step in the degeneration process.

Conclusions:

  • cADPR acts as a crucial downstream effector of Sarm1 activation in chemotherapy-induced axonal degeneration.
  • Targeting the cADPR-mediated calcium influx pathway may offer therapeutic strategies against neurotoxicity.